Bausch Health Companies Inc. (BHC) 2015 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Angela, and I will be your conference operator. At this time, I would like to welcome, everyone, to the Valeant Pharmaceuticals' second-quarter 2015 financial results conference call.

    早安。我叫 Angela,將擔任本次會議的接線員。此刻,我謹代表主辦方歡迎各位參加 Valeant Pharmaceuticals 2015 年第二季財務業績電話會議。

  • (Operator Instructions)

    (接線員指示)

  • Thank you. I would now like to turn the conference to Ms Lori Little, Head of Investor Relations. Please go ahead.

    謝謝。現在我想把會議交給投資人關係主管 Lori Little 女士。請開始。

  • - Head of IR

    - Head of IR

  • Thanks, Angela. Good morning, everyone. Welcome to Valeant's investor conference call, where we will be discussing our second-quarter 2015 financial results. Participating on today's call are: J Michael Pearson, Chairman and Chief Executive Officer; Rob Rosiello, Chief Financial Officer; Dr Ari Kellen, Company Group Chairman; and Anne Whitaker, Company Group Chairman. In addition to a live webcast, a copy of today's slide presentation can be found on our website under the Investor Relations section.

    謝謝你,Angela。各位早安。歡迎參加 Valeant 的投資人電話會議,我們將在此討論 2015 年第二季財務業績。今天與會者包括:董事長兼執行長 J Michael Pearson;財務長 Rob Rosiello;公司事業群主席 Ari Kellen 醫師;以及公司事業群主席 Anne Whitaker。除即時網路直播外,今日簡報投影片亦可於本公司網站「投資人關係」專區取得。

  • Before we begin, our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation, as it contains important information.

    在開始之前,我們今天的簡報包含前瞻性資訊。請各位花點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。

  • In addition, this presentation contains non-GAAP financial measures. For more information about these non-GAAP financial measures, please refer to slide 2. Non-GAAP reconciliations can be found in the press release issued earlier today and posted on our website.

    此外,本簡報包含非 GAAP 財務衡量指標。關於這些非 GAAP 財務衡量指標的更多資訊,請參閱投影片第 2 頁。非 GAAP 調節表可見於今日稍早發布並已張貼於本公司網站的新聞稿中。

  • Finally, the financial guidance in this presentation is effective only as of today. It is our policy to update or affirm guidance only through broadly disseminated public disclosure. With that, I will turn the call over to Mike.

    最後,本簡報中的財務指引僅自今日起生效。本公司政策為僅透過廣泛散布的公開揭露更新或確認指引。接下來我把電話交給 Mike。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you, Laurie. Good morning, everyone. Thank you for joining us.

    謝謝你,Laurie。各位早安。感謝各位加入我們。

  • We are pleased to report exceptional results across all financial and operational metrics for our second quarter. Driven by a strong sales growth in profitability across our regions and businesses and once again demonstrating the strength of our diversified and decentralized business model.

    我們很高興報告,本公司第二季在所有財務與營運指標上都繳出卓越成果。在各地區與各事業的強勁銷售成長與獲利能力提升帶動下,再次展現我們多元化且分權式商業模式的實力。

  • Before we begin discussing the details of our performance, I wanted to provide the highlights of the quarter. We have now delivered four consecutive quarters of more than 15% same-store organic growth. Strong performance throughout our businesses resulted in both our top and bottom line exceeding the Q2 guidance that we provided on our last call. These results were driven by the continued outperformance of our US businesses and strong results around the world including Asia, Australia, Canada, Mexico, and the Middle East and North Africa.

    在開始討論我們表現的細節之前,我想先提供本季重點摘要。我們已連續四個季度達成超過 15% 的同店有機成長。各事業的強勁表現,使我們的營收與獲利(上、下線)皆超越上次電話會議所提供的第二季指引。這些成果主要來自美國事業持續優於預期的表現,以及全球多地的強勁結果,包括亞洲、澳洲、加拿大、墨西哥,以及中東與北非。

  • I am also pleased to report that Salix is off to a fast start. The productivity of Salix's R&D portfolio is demonstrated by the approval of Xifaxan for IBS-D in May and the NDA filing for Relistor Oral in June; two significant milestones for our GI business. We remain focused on reducing Salix's wholesaler inventory and are on plan.

    我也很高興報告,Salix 開局迅速。Salix 研發產品組合的生產力,體現在 5 月 Xifaxan 取得 IBS-D 適應症核准,以及 6 月 Relistor 口服劑型 NDA 送件;這是我們腸胃(GI)事業的兩項重要里程碑。我們仍專注於降低 Salix 的批發商庫存,且進度符合計畫。

  • Specifically, we have reduced inventory levels for Salix products to approximately 3 to 3.5 months as compared to 4 to 5 months at the April 1 close. Finally, we have already achieved $500 million in run-rate synergies and fully expect to achieve $530 million by the end of the year.

    具體而言,我們已將 Salix 產品的庫存水位降至約 3 至 3.5 個月,相較於 4 月 1 日交割完成時的 4 至 5 個月。最後,我們已達成 5 億美元的協同效益年化運行率(run-rate),並完全預期在年底前達到 5.3 億美元。

  • Third, Dendreon continues to exceed our expectations for both revenue and profitability. We achieved: $74 million in revenues through the second quarter, an increase of 18% versus the previous quarter; and gross margins of approximately 64%, an improvement of 15%. And operating margins of approximately 40% to 45%, which we expect to continue to improve through the remainder of the year. This is a huge turnaround for a Company that was unprofitable just last year.

    第三,Dendreon 在營收與獲利方面持續超出我們的預期。截至第二季,我們達成:營收 7,400 萬美元,較前一季成長 18%;毛利率約 64%,提升 15%。營業利益率約 40% 至 45%,我們預期在今年剩餘期間將持續改善。對一家去年還在虧損的公司而言,這是巨大的轉變。

  • On the business development front, we have remained quite active with eight tuck-in deals already signed and/or closed so far this year. Later in the presentation, we will provide an annual update on M&A performance since 2008.

    在業務開發方面,我們仍相當積極,今年迄今已簽署及/或完成 8 件補強型(tuck-in)交易。在簡報稍後,我們將提供自 2008 年以來併購(M&A)績效的年度更新。

  • Based on our strong base business performance and the approval of Xifaxan for IBS-D, we are raising 2015 cash EPS guidance to $11.50 to $11.80. Our revenue guidance, we're raising to $10.7 billion to $11.1 billion for the year. We continue to expect total company same-store sales organic growth to exceed 10% for the remainder of the year, despite the genericization of Targretin in July and the expected genericization of Xenazine in August.

    基於核心業務的強勁表現,以及 Xifaxan 取得 IBS-D 核准,我們將 2015 年現金 EPS 指引上調至 11.50 至 11.80 美元。我們也將全年營收指引上調至 107 億至 111 億美元。儘管 7 月 Targretin 存在學名藥化,以及預期 8 月 Xenazine 也將學名藥化,我們仍預期公司整體同店銷售有機成長在今年剩餘期間將超過 10%。

  • For the quarter, our total revenue was $2.7 billion, an increase of 34% over the prior year, largely driven by the exceptionally strong growth in many of our US businesses, which offset negative headwinds from foreign exchange. Adjusting for the negative impact of FX of $173 million, revenue grew 42% over Q2 2014. Cash EPS was $2.56, an increase of 34% over the prior year, which includes the negative impact of $0.13 from the strengthening US dollar. Adjusted for FX, cash EPS grew 41% over Q2 2014.

    本季總營收為 27 億美元,較去年同期成長 34%,主要由多項美國事業的異常強勁成長所帶動,抵銷了外匯帶來的不利影響。若調整外匯(FX)負面影響 1.73 億美元,營收較 2014 年第二季成長 42%。現金 EPS 為 2.56 美元,較去年同期成長 34%,其中包含美元走強帶來的 0.13 美元負面影響。若調整外匯影響,現金 EPS 較 2014 年第二季成長 41%。

  • As mentioned in our press release, Salix had a negative impact of $0.04 on our cash EPS this quarter; therefore, our cash EPS would have been $2.60 for the quarter without Salix. Rob will take you through the math later in the presentation.

    如同我們在新聞稿中提到的,Salix 本季對我們的現金 EPS 造成 0.04 美元的負面影響;因此,若不含 Salix,本季現金 EPS 將為 2.60 美元。Rob 將在簡報稍後帶各位計算其差異。

  • Turning to organic growth, our overall same-store total company organic growth was 19% for the quarter. The exceptional growth of our US businesses driven by the strength of dermatology, contact lenses, dental and Obagi was complimented by many of our emerging markets including China, Middle East/North Africa, Russia and South Korea. As we are now halfway through the year, our same-store sales organic growth was 17% for the first six months.

    談到有機成長,本季公司整體同店有機成長為 19%。美國事業的卓越成長,受惠於皮膚科、隱形眼鏡、牙科與 Obagi 的強勁表現;同時也受到多個新興市場的帶動,包括中國、中東/北非、俄羅斯與南韓。由於我們已走過上半年,前六個月的同店銷售有機成長為 17%。

  • Our overall pro forma total company organic growth was primarily impacted by Salix, as we continued to reduce inventory in the wholesaler channels. Salix's revenues declined by approximately $16 million in Q2 2015 as compared to Q2 2014. Our pro forma total company organic growth excluding Salix was 20%. B+ L continues to demonstrate strong organic growth led by Rx pharmaceuticals in the United States, our US contact lens business and our emerging markets.

    我們整體備考(pro forma)公司有機成長主要受到 Salix 影響,因我們持續降低批發通路的庫存。Salix 的營收在 2015 年第二季較 2014 年第二季約減少 1,600 萬美元。若排除 Salix,我們備考公司整體有機成長為 20%。B+L 仍持續展現強勁有機成長,主要由美國處方藥業務、我們的美國隱形眼鏡業務,以及新興市場所帶動。

  • Q2 revenues increased to $836 million from Q1 revenues of $745 million. We continue to expect B+ L organic growth to be approximately 10% for the full year. As we approach our two-year anniversary of the B+ L acquisition, we have fully integrated the business and manage it as an integrated iHealth portfolio; therefore, this will be the last quarter that we break out the US B+ L organic growth by sub category.

    第二季營收由第一季的 7.45 億美元增加至 8.36 億美元。我們仍預期 B+L 全年有機成長約為 10%。隨著我們接近收購 B+L 兩週年,我們已將該業務完全整合,並以整合後的 iHealth 產品組合進行管理;因此,這將是我們最後一季按子類別拆分揭露美國 B+L 的有機成長。

  • Turning to our Top 20 products. Our Top 20 products represented 40% of total second-quarter revenue, with the Top 10 products contributing approximately 28% of revenue. Our Top 20 products delivered organic same-store growth of 32% for the quarter.

    接著談我們的前 20 大產品。我們的前 20 大產品占第二季總營收的 40%,其中前 10 大產品約貢獻 28% 的營收。本季前 20 大產品帶來 32% 的有機同店成長。

  • Excluding new product acquisitions, roughly half of our growth came from volume and half came from price. Our largest product, Xifaxan, represented approximately 5% of Q2 revenues, despite revenues that were muted due to excess inventory in the channel.

    若排除新產品併購因素,我們的成長約有一半來自銷量、一半來自價格。我們最大產品 Xifaxan 約占第二季營收的 5%,儘管因通路庫存過高導致營收表現受到抑制。

  • Jublia is now our second largest product with annual run-rates sales of approximately $450 million. Due to the generic launch of Targretin in July and the generic launch of Xenazine expected in August, we believe both products will fall out of our Top 20 products in Q3. I would also like to note that one of our new products Glumetza loses it's patent protection in February 2016 and will fall out of the list in 2016.

    Jublia 現已成為我們第二大產品,年化銷售運行率約 4.5 億美元。由於 Targretin 已於 7 月推出學名藥,以及預期 Xenazine 將於 8 月推出學名藥,我們認為兩項產品在第三季將退出我們的前 20 大產品名單。我也要指出,我們的新產品之一 Glumetza 將於 2016 年 2 月失去專利保護,並將在 2016 年退出名單。

  • Our US dermatology business had another excellent quarter with our launch brands leading the way. Both launch and core brands contributed to the dermatology revenue growth of 55% year-on-year. Jublia scripts grew 37% in Q2 versus Q1, which points to an increase of 55% on a 4-millimeter equivalent basis. Our DTC campaign featuring John McEnroe is having a positive impact on the product and continues to expand prescribing volume, particularly with the primary care physician base.

    我們的美國皮膚科業務本季再度表現出色,由上市新品品牌領軍。上市新品與核心品牌共同推動皮膚科營收年增 55%。Jublia 第二季處方量較第一季成長 37%,換算為 4 毫米等效基礎,顯示成長 55%。由 John McEnroe 代言的 DTC(直接面向消費者)活動對產品帶來正面影響,並持續擴大處方量,尤其是在基層照護醫師族群。

  • Onexton has demonstrated rapid TRx uptake since its January launch and recently reached 8,000 scripts per week. The fully-integrated DCT campaign with TV, print and digital is accelerating growth. The current annualized run-rate for Onexton is approximately $70 million.

    Onexton 自 1 月上市以來,TRx(總處方量)快速攀升,近期已達每週 8,000 張處方。涵蓋電視、平面與數位的全整合 DTC 活動正加速成長。Onexton 目前的年化運行率約為 7,000 萬美元。

  • Luzu scripts have reached a new record high with volume up 55% relative to Q1. Luzu continues to grow with our new DTC campaign driving awareness. The current annualized run-rate for Luzu is approximately $26 million. Lastly, our script trends for our base dermatology business, including Solodyn, Ziana, Atralin, Elidel and Zyclara are all demonstrating strong double-digit growth rates.

    Luzu 處方量創下新高,較第一季增加 55%。在我們新的 DTC 活動提升認知度的帶動下,Luzu 持續成長。Luzu 目前的年化運行率約為 2,600 萬美元。最後,我們基礎皮膚科業務的處方趨勢(包括 Solodyn、Ziana、Atralin、Elidel 與 Zyclara)皆呈現強勁的雙位數成長率。

  • Our US eye health business continued its strong growth trend and delivered 10% growth over the prior year. Contact lens grew 19% organically over the prior year. Biotrue ONEday continues to grow 4 times faster than its category. Based on the growth of the Biotrue franchise over the last five quarters, six additional Biotrue lines are currently planned.

    我們的美國眼健康業務延續強勁成長趨勢,較去年成長 10%。隱形眼鏡業務較去年有機成長 19%。Biotrue ONEday 的成長速度持續為其品類的 4 倍。基於 Biotrue 系列過去五個季度的成長,目前規劃再推出 6 條 Biotrue 產品線。

  • B+ L's ULTRA contact lens continues to be well received by eye care professionals. Our first commercial manufacturing line for ULTRA is operational. We continue to sell to capacity. We recently approved lines five and six for ULTRA to support the long-term global demand.

    B+L 的 ULTRA 隱形眼鏡持續獲得眼科照護專業人士的高度肯定。我們第一條 ULTRA 商業化製造產線已投入運作。我們持續以滿載產能銷售。近期我們已核准 ULTRA 的第 5 與第 6 條產線,以支援長期的全球需求。

  • Our prescription drug ophthalmology business continues to see strong -- extremely strong growth across promoted brands fueled by the Lotemax Franchise and Prolensa. We are also quite pleased to announce that we have filed Vesneo with the FDA.

    我們的處方藥眼科業務在重點推廣品牌上持續呈現強勁——極為強勁——的成長,主要由 Lotemax 系列與 Prolensa 帶動。我們也很高興宣布,已向 FDA 遞交 Vesneo 申請。

  • Organic growth for surgical was 1% for the quarter. Adjusted for the continued shift from the sale -- from sales to leasing models of femtosecond lasers, organic growth would have been 3%. We expect to see improving organic growth for surgical for the remainder of the year, driven by market share gains across our product lines including our IOL's and our surgical equipment.

    本季手術業務的有機成長為 1%。若調整持續從銷售模式——從銷售轉向租賃模式的飛秒雷射設備之影響,有機成長本可達 3%。我們預期今年剩餘期間手術業務的有機成長將改善,動能來自我們各產品線(包括 IOL(人工水晶體)與手術設備)的市占率提升。

  • The strong performance of neuro and other, as well as the generics portfolio was driven by promoted brands including Aplenzin, Cuprimine and Syprine. In our consumer business, CeraVe, Preservision and BioTrue MultiPurpose Solution all demonstrated strong double-digit growth demand.

    神經科與其他業務以及學名藥產品組合的強勁表現,主要由重點推廣品牌(包括 Aplenzin、Cuprimine 與 Syprine)所帶動。在消費者業務方面,CeraVe、Preservision 與 BioTrue 多功能護理液皆展現強勁的雙位數需求成長。

  • Finally, our dental business continued its track record of strong double-digit growth. In March, we expanded our dental product portfolio through the acquisition of Neutrasal, a treatment for general dry mouth and oral mucositis.

    最後,我們的牙科業務延續強勁的雙位數成長紀錄。3 月我們透過收購 Neutrasal 擴充牙科產品組合;Neutrasal 用於治療一般口乾與口腔黏膜炎。

  • When we acquired Neutrasal, its annual revenues were approximately $8 million. After four months, the run-rate revenue for Neutrasal is over $16 million. This is another example of our ability to quickly have an impact on our acquisitions.

    我們收購 Neutrasal 時,其年營收約為 800 萬美元。四個月後,Neutrasal 的運行率營收已超過 1,600 萬美元。這再次展現我們能迅速讓併購案產生影響的能力。

  • Now, turning to the rest of the world. In our emerging markets, organic growth for our business in Asia was 10% versus the prior year. We continued to see strong growth in a number of countries, including China at 15% and South Korea at 23%.

    接著談全球其他地區。在新興市場方面,我們亞洲業務的有機成長較去年為 10%。我們在多個國家持續看到強勁成長,包括中國 15% 與南韓 23%。

  • In Latin America, we delivered 7% organic growth, with Mexico at 12%, offsetting more modest growth in Brazil and Argentina. Central and Eastern Europe, the Middle East/North Africa delivered strong double-digit growth of 18%. Russia returned a positive organic growth this quarter.

    在拉丁美洲,我們達成 7% 的有機成長,其中墨西哥 12%,抵銷了巴西與阿根廷較為溫和的成長。中東歐以及中東/北非地區交出 18% 的強勁雙位數成長。俄羅斯本季恢復正向的有機成長。

  • Overall growth in other Central and Eastern European countries were slightly negative this quarter as they were primarily impacted by Ukraine and Greece. For the rest of the world developed markets, the underlying business remained strong with our Australian, Canadian and Western European businesses performing well, with 6%, 7% and 5% organic growth respectively.

    本季其他中東歐國家的整體成長略為負值,主要受到烏克蘭與希臘的影響。至於全球其他已開發市場,基本面仍然強勁;我們在澳洲、加拿大與西歐的業務表現良好,有機成長分別為 6%、7% 與 5%。

  • Now let me turn to the Salix acquisition. We completed our acquisition of Salix on April 1. We have already achieved several significant R&D milestones with the approval of Xifaxan for IBS-D, the submission of Relistor Oral NDA and the approval of the Relistor injection in Europe.

    接著我談 Salix 併購案。我們已於 4 月 1 日完成對 Salix 的收購。我們已在研發方面達成數項重要里程碑,包括 Xifaxan 取得 IBS-D 適應症核准、提交 Relistor 口服劑型 NDA,以及 Relistor 注射劑在歐洲獲准。

  • Obviously, the big event was the IBS-D approval where we saw immediate growth in script uptake of Xifaxan post-approval. Our soft launch commenced right after approval with our sales force undergoing training the first week of June. At this time, we continue to promote the package insert as we are still awaiting regulatory approval for our marketing campaign, including our first DTC advertisement.

    顯然,最大的事件是 IBS-D 的核准;核准後我們立即看到 Xifaxan 的處方量快速成長。我們在核准後隨即啟動軟性上市,並於 6 月第一週對業務團隊進行訓練。目前我們仍持續以仿單內容作為推廣重點,因為我們仍在等待行銷活動(包括第一支 DTC 廣告)的監管核准。

  • Based on our quick start, revenues and EBITDA are both significantly ahead of the deal model and the integration is nearly completed. In addition to the realignment of the sales force, which we discussed in our last earnings call, we revamped the sales-force compensation model to be in line with our existing performance-based compensation structure versus Salix's structure which force-ranked the sales team. We believe these adjustments will maximize the effectiveness of our sales team going forward.

    基於我們的快速起步,營收與 EBITDA 皆顯著優於交易模型預期,整合也幾乎完成。除了我們在上次法說會中提到的業務團隊重整之外,我們也重新設計了業務團隊的薪酬模式,使其與我們既有的績效導向薪酬架構一致,而非沿用 Salix 對業務團隊進行強制排名的制度。我們相信這些調整將在未來最大化業務團隊的效能。

  • Finally as I mentioned earlier, we are pleased to report that our wholesale inventory reduction program is on plan. We are currently at approximately 3 to 3.5 months as compared to 4 to 5 months at the April 1 close. We still expect inventory levels to be reduced to 1.5 months or less by year-end. Rob will take you through the details later in the call.

    最後,如我先前提到的,我們很高興報告,我們的批發庫存削減計畫正按計畫進行。目前我們約為 3 到 3.5 個月,相較於 4 月 1 日結帳時的 4 到 5 個月。我們仍預期在年底前將庫存水位降至 1.5 個月或更低。Rob 稍後會在電話會議中帶各位了解細節。

  • As slide 15 shows, we have experienced a significant increase in script trends from 15% to 33% year-over-year growth for Xifaxan since the approval for IBS-D on May 27. Following the close of the acquisition, we held a pipeline review session with the Salix R&D team, the Valeant R&D team and several external experts. The purpose of the session was to provide an in-depth discussion of the pipeline products and determine which ones would move forward. I am pleased to report that a vast majority of the programs are still ongoing and are detailed on slide 16.

    如投影片 15 所示,自 5 月 27 日 IBS-D 適應症獲准以來,Xifaxan 的處方趨勢年增率已由 15% 大幅提升至 33%。在收購完成後,我們與 Salix 研發團隊、Valeant 研發團隊以及數位外部專家舉行了產品線(pipeline)審查會議。該會議的目的在於就產品線中的產品進行深入討論,並決定哪些項目將繼續推進。我很高興報告,絕大多數計畫仍在進行中,並已在投影片 16 中詳述。

  • As expected, we continue to be very active in the business to all MENA activities. We have closed or signed eight deals so far this year, with the most significant one being Amoun, an acquisition we announced last week. This acquisition adds approximately $225 million to our existing Middle East/North Africa sales, which is one of the fastest growing emerging markets in the world. Including Amoun, our Middle East business will be approximately $500 million in 2016.

    如預期,我們在所有 MENA 相關業務活動方面仍非常積極。今年迄今我們已完成或簽署八筆交易,其中最重要的是 Amoun——我們於上週宣布的一項收購案。此收購將為我們既有的中東/北非銷售額新增約 2.25 億美元;該地區是全球成長最快的新興市場之一。包含 Amoun 在內,我們 2016 年的中東業務規模將約為 5 億美元。

  • As we have mentioned for a number of quarters, we're continuing to look for opportunities to grow in Latin America. We recently agreed to acquire Humax, a branded generics company in Columbia that provides us entry into a new market and will compliment our current business in Mexico. Finally, we have recently agreed to buy Commonwealth Diagnostics, a company that sells a recently approved test for IBS-D. We believe this test will represent an important piece of our efforts to tap into the under-diagnosed IBS-D patient population.

    如我們在過去數個季度所提到的,我們持續尋找在拉丁美洲成長的機會。我們近期同意收購 Humax——一家位於哥倫比亞的品牌學名藥公司,這將使我們進入一個新市場,並與我們在墨西哥的既有業務形成互補。最後,我們近期也同意收購 Commonwealth Diagnostics——一家銷售一項近期獲准之 IBS-D 檢測的公司。我們相信,該檢測將成為我們切入尚未被充分診斷之 IBS-D 病患族群的重要一環。

  • When we embarked on our new strategy in 2008, we began to acquire assets that would build a strong foundation and fuel future growth. Since 2008, we have completed over 140 acquisitions, license deal and co-promote agreements and deployed over $40 billion in capital.

    當我們於 2008 年啟動新策略時,便開始收購資產,以建立堅實基礎並推動未來成長。自 2008 年以來,我們已完成超過 140 起收購、授權交易與共同推廣協議,並投入超過 400 億美元資本。

  • Our IRR hurdles continue to be the highest in the industry. We target IRR's of at least 20% based on local statutory tax rates and a cash payback period of six years or less. We monitor the process of each deal by tracking both top line and EBITDA by quarter.

    我們的 IRR 門檻仍為業界最高。我們以當地法定稅率為基礎,目標 IRR 至少 20%,且現金回收期為六年或更短。我們透過按季追蹤營收(top line)與 EBITDA 來監控每筆交易的進展。

  • We share these results with our Board of Directors every quarter and provide an update to investors on an annual basis. Today is that update. I'd also like to note that senior management's compensation is tied to past deal performance.

    我們每季都會與董事會分享這些結果,並每年向投資人提供一次更新。今天就是那次更新。我也想指出,高階管理團隊的薪酬與過往交易表現掛鉤。

  • As we break down our deal performance into large, medium and small deals, our track record, I believe speaks for itself. Our large transactions such as Biovail, Medicis, Bausch + Lomb, and Salix have all performed in line or ahead of the deal model. We believe there are several factors contributing to the success of our large deals, including the benefits of our decentralized model, detailed review of key business drivers and pipeline or other unexpected product upsides.

    當我們將交易表現拆分為大型、中型與小型交易時,我認為我們的成績不言自明。我們的大型交易,例如 Biovail、Medicis、Bausch + Lomb 與 Salix,皆與交易模型一致或優於交易模型。我們認為有數項因素促成大型交易的成功,包括去中心化模式的效益、對關鍵業務驅動因素的詳盡審查,以及產品線或其他未預期的產品上行空間。

  • For our medium sized deals, those $300 million to $1 billion, 10 of the 11 transactions are tracking towards or delivering well above our 20% IRR hurdle. All have delivered above our cost of capital. We have had a number of home runs in this category, including Ortho, Dermik, Aton and Sanitas.

    就我們的中型交易而言,即 3 億至 10 億美元規模的交易,11 筆交易中有 10 筆正朝向或已交出遠高於我們 20% IRR 門檻的表現。全部都高於我們的資本成本。在此類別中我們也有多筆「全壘打」交易,包括 Ortho、Dermik、Aton 與 Sanitas。

  • Finally, our small deals, approximately 50 are small acquisitions -- approximately 50 which are less than $300 million (inaudible), in aggregate are performing well above expectation, that is greater than returning an -- returning an IRR of greater than 20%. This category also includes several home run deals, deals of greater than 35% IRR fully taxed, such as Coria, Natur Produkt and Targretin. While we have had great success on the small deal front, we do have four failed deals, which performed lower cost of capital: Neotensil in the US; Vita Direct in Russia; PFI in Australia; and Vital Science in Canada.

    最後,我們的小型交易,約 50 筆小型收購——約 50 筆低於 3 億美元的交易(聽不清),合計表現遠高於預期,也就是回報——回報的 IRR 高於 20%。此類別也包含數筆「全壘打」交易,即在完全課稅後 IRR 超過 35% 的交易,例如 Coria、Natur Produkt 與 Targretin。雖然我們在小型交易方面非常成功,但也有四筆失敗交易,其表現低於資本成本:美國的 Neotensil;俄羅斯的 Vita Direct;澳洲的 PFI;以及加拿大的 Vital Science。

  • We have analysed the performance across all of our deals since 2008. Our achieved cumulative EBITDA exceeds our deal models by 18%. This reflects performance of our deals before applying the benefits of our lower tax rate. On a cumulative net income basis, the deal model net income reflects our analysis using the statutory tax rates, the approach we take when reviewing potential acquisitions.

    我們已分析自 2008 年以來所有交易的表現。我們實現的累計 EBITDA 較交易模型高出 18%。這反映的是在尚未納入我們較低稅率效益之前的交易表現。在累計淨利基礎上,交易模型的淨利反映我們使用法定稅率所做的分析——這也是我們審視潛在收購時採用的方法。

  • The cumulative achieved net income includes the benefit of our lower tax rate. When comparing the deal model and the accumulated -- achieved accumulative net income, our achieved outcome exceeds our deal models by 59%. Based on our performance of deal to date, our expected IRR excluding the benefit of our tax rate is approximately 26%. Our expected IRR including the benefit of our tax rate is greater than 37%.

    累計實現的淨利包含我們較低稅率所帶來的效益。比較交易模型與累計——實現的累計淨利後,我們的實際結果較交易模型高出 59%。根據迄今的交易表現,若不含稅率效益,我們的預期 IRR 約為 26%。若包含稅率效益,我們的預期 IRR 高於 37%。

  • The important part of our deal analysis is our targeted six-year payback period. We have reviewed our largest deals since 2008. We are pleased to report that five of these deals have already been paid back entirely including Coria, Dow, Aton, Biovail, Ortho and Dermik. While many of the small or mid-sized deals, including Targretin, Elidel and Tecnofarma, which are not included on this page, have also been paid back.

    我們交易分析中重要的一環是我們所設定的六年回收期目標。我們已檢視自 2008 年以來最大型的交易。我們很高興報告,其中有五筆交易已完全回收,包括 Coria、Dow、Aton、Biovail、Ortho 與 Dermik。此外,許多未列於本頁的小型或中型交易(包括 Targretin、Elidel 與 Tecnofarma)也已完成回收。

  • Other deals, such as B+ L, are on track to meet their expected payback period. B+ L is approximately 30% paid back after less than two years since the closing of the acquisition. Since the time of the acquisition, B+ L has delivered approximately 30% of Valeant's total EBITDA. I'd also like to note that B+ L, our largest deal prior to Salix -- we have improved organic growth from 2% to 9% since the acquisition, demonstrating our ability to create value under the Valeant business model.

    其他交易,例如 B+L,正按計畫達成其預期回收期。B+L 在收購完成後不到兩年,已回收約 30%。自收購以來,B+L 已貢獻約占 Valeant 總 EBITDA 的 30%。我也想指出,B+L 是我們在 Salix 之前最大的一筆交易——自收購以來,我們已將其有機成長率由 2% 提升至 9%,展現我們在 Valeant 商業模式下創造價值的能力。

  • One of the more important parts of our internal deal review is looking back at past acquisitions to determine what has contributed to our success and failure. Slides 24 and 25 outline our key learnings from the acquisitions.

    我們內部交易審查中較重要的一部分,是回顧過往收購,以判斷哪些因素促成了我們的成功與失敗。投影片 24 與 25 概述了我們從這些收購中得到的關鍵學習。

  • Now, I will turn the call over to Rob.

    現在,我將把電話會議交給 Rob。

  • - CFO

    - CFO

  • Mike already described our exceptional Q2 results. Our revenue of $2.7 billion exceeded the mid-point of the guidance we provided during our Q1 earnings call by approximately $200 million, primarily driven by the outperformance of our US businesses, including dermatology, contact lenses and dentistry. Our overall cost of goods sold improved to 23% in the second quarter, primarily due to the continued growth in dermatology, as well as the acquisition of Salix, resulting in improved gross margins of 77%.

    Mike 已經說明了我們第二季的卓越業績。我們的營收為 27 億美元,較我們在第一季財報電話會議中提供的指引中位數高出約 2 億美元,主要由我們美國業務的優於預期所帶動,包括皮膚科、隱形眼鏡與牙科。第二季我們整體銷貨成本改善至 23%,主要受惠於皮膚科持續成長,以及收購 Salix,帶動毛利率提升至 77%。

  • SG&A remains above historical levels, but improved by 1 point from last quarter on an overall basis, despite increased costs associated with our launch initiatives. In the second quarter, we spent approximately $60 million in DTC advertising supporting Jublia, Onexton and Luzu. The overall improvement also demonstrates our rapid synergy capture from the Salix integration. R&D was $81 million in the quarter, an increase of approximately 45% relative to Q1, reflecting our continued investment in legacy Valeant programs and the addition of the Salix programs described earlier.

    SG&A 仍高於歷史水準,但整體而言較上季改善 1 個百分點,儘管我們的上市推廣計畫相關成本增加。第二季,我們在 DTC(直接面向消費者)廣告上投入約 6,000 萬美元,以支持 Jublia、Onexton 與 Luzu。整體改善也顯示我們在 Salix 整合中快速取得協同效益。本季研發費用為 8,100 萬美元,較第一季增加約 45%,反映我們持續投資於 Valeant 既有專案,以及新增前述 Salix 專案。

  • As Mike mentioned, Salix contributed negative $0.04 in cash EPS for quarter, taking into consideration the incremental interest and incremental shares related to the Salix financing. Valeant, excluding Salix, showed an even stronger sequential and year-over-year cash EPS. Legacy Valeant's top line organic growth and improved product mix more than offset increased investment in our launch brands.

    如 Mike 所提到,Salix 本季對現金 EPS 的貢獻為負 0.04 美元,已考量 Salix 融資所帶來的新增利息與新增股數。不含 Salix 的 Valeant,其現金 EPS 無論季比或年比都更為強勁。傳統 Valeant 的營收有機成長與產品組合改善,足以抵銷我們對上市品牌增加的投資。

  • Turning to slide 28. The acquisition of Salix had an even more significant impact on GAAP cash flow than adjusted cash flow. Valeant's GAAP cash flow excluding Salix was substantial, at $714 million. There were minimal add-backs to arrive at adjusted cash flow of $770 million.

    接著看第 28 頁投影片。收購 Salix 對 GAAP 現金流的影響甚至比對調整後現金流更為顯著。不含 Salix 的 Valeant GAAP 現金流相當可觀,為 7.14 億美元。為得出 7.70 億美元的調整後現金流,加回項目很少。

  • Salix had negative GAAP cash flow of $303 million, driven by significant cash charges related to: unvested equity awards; restructuring charges, primarily severance; and the buildup of accounts receivable and growth to nets of $96 million. In Q2, Salix contributed $3 million to our adjusted cash flow. Starting in Q3, we expect our aggregate cash flow to improve significantly as Salix's inventory normalizes and one-time restructuring items are reduced.

    Salix 的 GAAP 現金流為負 3.03 億美元,主要由以下重大現金費用所致:未歸屬的股權獎勵;重整費用(主要為資遣費);以及應收帳款增加與「成長至淨額」(growth to nets)增加 9,600 萬美元。第二季,Salix 對我們的調整後現金流貢獻為 300 萬美元。自第三季起,隨著 Salix 庫存回歸正常且一次性重整項目減少,我們預期合併現金流將顯著改善。

  • Cash conversion for both the Valeant stand-alone and overall business was 86%, reflecting our continued investment in working capital to support the exceptional growth of our business. Given our acquisition of Salix, our goal is to achieve 90% cash conversion by the end of the year. As we have discussed, we plan to reduce inventory levels for Salix to 1.5 months or less, ideally 1 month by year-end.

    Valeant 單體與整體業務的現金轉換率均為 86%,反映我們持續投入營運資金以支持業務的卓越成長。鑑於我們收購 Salix,我們的目標是在年底前達成 90% 的現金轉換率。如先前所討論,我們計畫將 Salix 的庫存水位降至 1.5 個月或更低,理想情況是在年底前降至 1 個月。

  • Currently, individual wholesalers have varying amounts of inventory for specific Salix products. So while we continue to work down inventory, wholesalers are placing orders for specific products where inventories have been reduced to our targeted levels. For Q3, we expect our reported net sales for Salix to be about the same as Q2 sales or approximately $300 million, due to the continued reduction in wholesaler inventory levels. By the end of Q4, we expect to normalize inventories and enter 2016 with sales reflecting actual product demand.

    目前,各個批發商對特定 Salix 產品持有的庫存量不一。因此,當我們持續去化庫存時,批發商也會針對庫存已降至我們目標水準的特定產品下單。就第三季而言,由於批發商庫存水位持續下降,我們預期 Salix 的申報淨銷售額將與第二季大致相同,約為 3 億美元。到第四季末,我們預期庫存將正常化,並以反映實際產品需求的銷售水準進入 2016 年。

  • On slide 3, in Q2, we incurred restructuring and integration expenses of $153 million, approximately $122 million of this quarter's charges relate to Salix. We expect to realize up to an additional $175 million of charges for Salix during the remainder of 2015. We also recorded $18 million of charges related to Dendreon. We expect any additional charges for Dendreon for the remaining of the year to be minimal.

    在第 3 頁投影片,第二季我們發生重整與整合費用 1.53 億美元,其中約 1.22 億美元與 Salix 相關。我們預期 2015 年剩餘期間,Salix 可能還會產生最多額外 1.75 億美元的費用。我們也認列了與 Dendreon 相關的 1,800 萬美元費用。我們預期今年剩餘期間 Dendreon 的任何額外費用將很少。

  • Bausch + Lomb restructuring is complete. Restructuring and integration charges for other recent small deals were approximately $13 million this quarter. For the remainder of the year, we expect less than $20 million of incremental charges for deals already closed, excluding Salix and Dendreon. This guidance excludes any deals that have not yet closed and any new deals that might occur.

    Bausch + Lomb 的重整已完成。本季其他近期小型交易的重整與整合費用約為 1,300 萬美元。在今年剩餘期間,對於已完成交割的交易(不含 Salix 與 Dendreon),我們預期新增費用將少於 2,000 萬美元。此指引不包含尚未完成交割的交易,以及可能發生的任何新交易。

  • In terms of our balance sheet, we ended the quarter with a strong liquidity position through a combination of a $1.5 billion undrawn revolver and $958 million of cash on hand. Our net debt to pro forma adjusted EBITDA ratio was approximately 5.5 times. We remain committed to reducing that ratio to below 4 times by the end of 2016. During the quarter, we opportunistically repurchased $50 million in Valeant equity at $223 per share. Our accounts receivable DSO's improved this quarter as compared to the second quarter of 2014 at 65 days.

    就資產負債表而言,本季末我們透過 15 億美元未動用的循環信貸額度以及 9.58 億美元的手頭現金,維持強勁的流動性部位。我們的淨負債對備考調整後 EBITDA 比率約為 5.5 倍。我們仍致力於在 2016 年底前將該比率降至 4 倍以下。本季我們把握時機,以每股 223 美元回購 5,000 萬美元的 Valeant 股權。本季我們的應收帳款 DSO(應收帳款週轉天數)較 2014 年第二季的 65 天有所改善。

  • 2015 continues to be a strong year for our Company. Based on the continued outperformance of Valeant's business and the approval of Xifaxan for IBS-D, we are increasing our 2015 guidance. Given the Salix inventory situation, we are making an exception to past practices and are providing Q3 and Q4 guidance. Until Salix is fully normalized, we feel it is important to provide investors with this information.

    2015 年對本公司而言仍是強勁的一年。基於 Valeant 業務持續優於預期,以及 Xifaxan 獲准用於 IBS-D,我們上調 2015 年指引。鑑於 Salix 的庫存狀況,我們破例不同於以往作法,提供第三季與第四季指引。在 Salix 完全正常化之前,我們認為向投資人提供此資訊很重要。

  • For 2015, we are increasing our guidance for revenue to $10.7 billion to $11.1 billion from $10.4 billion to $10.6 billion. We had previously guided that Salix revenues would be $1 billion for the year. Given the approval of the Xifaxan IBS-D indication and progression of the planned reduction in wholesaler inventories, we are taking our 2015 guidance for Salix revenues up to $1.2 billion. We are also increasing our guidance for cash EPS to $11.50 to $11.80 from $10.90 to $11.20; and our adjusted cash flow from operations guidance to greater than $3.2 billion from greater than $3.1 billion for the year.

    就 2015 年而言,我們將營收指引由 104 億至 106 億美元上調至 107 億至 111 億美元。我們先前指引 Salix 全年營收為 10 億美元。鑑於 Xifaxan IBS-D 適應症獲准,以及批發商庫存按計畫持續下降,我們將 2015 年 Salix 營收指引上調至 12 億美元。我們也將現金 EPS 指引由 10.90 至 11.20 美元上調至 11.50 至 11.80 美元;並將全年營運活動調整後現金流指引由大於 31 億美元上調至大於 32 億美元。

  • Our Q3 and Q4 guidance reflects both the expected generic impact from Targretin and Xenazine, as well as the Salix inventory drawdown program still underway. We expect our same-store organic growth to be greater than 10% for the second half of the year, despite the impact of generic entrance for Targretin in July and the expected generic entrance for Xenazine in August.

    我們的第三季與第四季指引同時反映 Targretin 與 Xenazine 的預期學名藥影響,以及仍在進行中的 Salix 庫存去化計畫。儘管 7 月 Targretin 學名藥上市以及預期 8 月 Xenazine 學名藥上市帶來影響,我們仍預期下半年同店有機成長將超過 10%。

  • Finally, although I will not go through all of our key assumptions used to build our forecast, they are listed on slide 33 for your reference. Now I would like to turn the call back over to Laurie.

    最後,雖然我不會逐一說明用來建立我們預測的所有關鍵假設,但它們已列在第 33 頁投影片供各位參考。現在我想把電話會議交回給 Laurie。

  • - Head of IR

    - Head of IR

  • Thanks, Rob. Before we open the call to questions, I'd like to remind everyone that in order to ensure that we have adequate time to take everyone's questions, we will only take one question per caller. If you'd like to ask a follow-up question, you're welcome to get back in the queue.

    謝謝你,Rob。在我們開放提問之前,我想提醒各位,為了確保我們有足夠時間回答大家的問題,我們將每位來電者只接受一個問題。如果您想追問,歡迎您重新排隊。

  • We'll try and take as many questions as possible in the time allotted. With that, we will take our first question.

    我們會在既定時間內盡可能回答更多問題。那麼,我們開始第一個問題。

  • Operator

    Operator

  • Chris Schott, JPMorgan.

    Chris Schott,摩根大通(JPMorgan)。

  • - Analyst

    - Analyst

  • Congrats on the very strong results here.

    恭喜你們取得非常強勁的成果。

  • Mike, Can you just elaborate a little bit more on the Xifaxan launch in IBS-D? Just, specifically, how should we think about the rest of the year in terms of priorities for the organization? When should we think about DTC really starting to roll out? Are you comfortable at this point giving us a little bit more color in terms of peak sales opportunity for this particular indication? Thanks very much.

    Mike,你能否再多談一點 Xifaxan 在 IBS-D 的上市推廣?具體來說,就今年剩餘時間而言,我們應該如何看待組織的優先事項?我們應該何時預期 DTC 真的開始逐步推出?就這個特定適應症的峰值銷售機會而言,你現在是否願意提供更多細節?非常感謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Hi, Chris. Thank you.

    嗨,Chris。謝謝你。

  • We've submitted the marketing materials to the Agency. We hope to get those approved sometime in August -- unfortunately probably late August. So our current expectation is we'll roll out our DTC program in September. We plan for a very heavy spend in the back half of the year, actually much higher than we had for Jublia last year. As long as it, again, keeps working like it has for Jublia, continue that spend.

    我們已將行銷素材提交給主管機關。我們希望能在八月某個時間獲得核准——不幸的是可能會是八月底。因此,我們目前的預期是在九月推出我們的 DTC 計畫。我們計畫在下半年投入非常高的費用,實際上會遠高於去年 Jublia 的投入。只要它——再次強調——能像 Jublia 一樣持續有效,我們就會延續這樣的投入。

  • We are not going to give a peak sales yet. We're not ready to give a peak sales yet for IBS-D. We'll pull the whole sales force -- all the sales forces in that are going to be selling the IBS-D indication in late August, and have at launch meet as well. We also recently decided to actually create a fifth specialty sales force covering GI and doctors who have the potential to prescribe Xifaxan. So we'll now have five sleeves rather than four sleeves.

    我們目前不會提供峰值銷售預估。我們還沒準備好提供 IBS-D 的峰值銷售預估。我們會在八月底把所有將負責銷售 IBS-D 適應症的銷售團隊全部召集起來,並且也會舉行上市啟動會。我們最近也決定實際上成立第五支專科銷售團隊,涵蓋腸胃科(GI)以及有可能開立 Xifaxan 的醫師。因此我們現在將有五個「銷售分隊(sleeves)」而不是四個。

  • Operator

    Operator

  • Andrew Finkelstein, Susquehanna Financial.

    Andrew Finkelstein,Susquehanna Financial。

  • - Analyst

    - Analyst

  • Congratulations on the results.

    恭喜你們的成果。

  • Perhaps you could address it in a bit more detail, what you're seeing in the global eye care market? Particularly -- where are you taking share? One of your competitors had a much more challenging quarter in that area, so maybe you can talk a bit about what differentiates your growth profile there? Then, bigger picture -- as you think about this spending level, as you've talked about some of the incremental investments you're making. But as we look out to next year, has the level of SG&A and R&D investment you're thinking about changed from what you had previously talked about for 2016? Thanks.

    也許你可以更詳細地談談你們在全球眼科護理市場看到的情況?特別是——你們是在哪些領域取得市占?你們的一位競爭對手在該領域本季表現更具挑戰性,所以也許你可以談談是什麼讓你們在那裡的成長輪廓有所差異?另外,從更宏觀的角度——當你們思考這個支出水準、以及你們提到的一些增量投資。但當我們展望明年時,你們對 2016 年的 SG&A 與研發(R&D)投資水準的想法,是否相較於先前談到的有所改變?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Sure. In eye care, it's a category that has a number of great companies competing in it. I think we've just been a little bit lucky in having some great new products that we've been able to introduce into the market. So I talked about the BioTrue ONEday, which is doing extremely well. It's a great contact lens; very comfortable. I think it's certainly doing extremely well. ULTRA, I think is going to be better than that. It's a great lens too. So we're the beneficiaries of having some newer products. I think we've also reorganized our business into local teams. Through our decentralized model, I think that's really helping in terms of -- so, we are gaining share in contact lenses. We are gaining share, I think, in the Rx products. We are gaining share in surgical. But I think it's a combination of some great products and a really focussed and talented team.

    當然。在眼科護理方面,這是一個有許多優秀公司競爭的類別。我想我們只是比較幸運,擁有一些很棒的新產品能夠導入市場。所以我提到 BioTrue ONEday,它表現非常好。這是一款很棒的隱形眼鏡;非常舒適。我認為它確實表現非常出色。我認為 ULTRA 會比那個更好。它也是一款很棒的鏡片。所以我們受惠於擁有一些較新的產品。我想我們也把業務重組為在地團隊。透過我們的分權模式,我認為這在——也就是在幫助我們——因此,我們在隱形眼鏡上正在提升市占。我認為我們在處方(Rx)產品上也正在提升市占。我們在手術相關領域也正在提升市占。但我認為這是一些很棒的產品,加上一支非常專注且有才華的團隊的綜合結果。

  • We are not going to give guidance on 2016 yet. In terms of philosophically, we have not changed our view in terms of what we think R&D and sales and marketing spend should be for the Company.

    我們目前還不會提供 2016 年的指引。就理念上而言,我們對於公司研發以及銷售與行銷支出應該是多少的看法,並沒有改變。

  • Operator

    Operator

  • Louise Chen, Guggenheim Securities.

    Louise Chen,Guggenheim Securities。

  • - Analyst

    - Analyst

  • It's Brandon on for Louise. We'd like to get your views of whether you're still interested in animal health? If so, why? Why not? Thank you.

    我是 Brandon,代 Louise 提問。我們想了解你們是否仍對動物保健有興趣?如果有,為什麼?如果沒有,為什麼不?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • We're not going to comment on future acquisitions.

    我們不會評論未來的併購。

  • Operator

    Operator

  • Annabel Samimy, Stifel.

    Annabel Samimy,Stifel。

  • - Analyst

    - Analyst

  • Congratulations on the quarter.

    恭喜本季表現。

  • You've pretty successfully added some very strong sources of organic growth. You have some meaningful franchises now. It looks like your M&A activity is going a little bit back to the bolt-on. Is this what we can expect -- from like, right now? How do you see the pricing environment in the different regions looking? How does that drive your M&A strategy?

    你們相當成功地新增了一些非常強勁的內生成長來源。你們現在也有一些具規模的重要產品線(franchises)。看起來你們的併購活動有點回到補強型(bolt-on)。這是我們可以預期的——從現在開始?你們如何看待不同地區的定價環境?這又如何影響你們的併購策略?

  • - Chairman & CEO

    - Chairman & CEO

  • Sure. I think our M&A strategy will always be a question of the tuck-ins or bolt-ons as you referenced, and opportunistically, larger acquisitions. One can never predict the timing of a larger acquisition, so when those happen, those happen. We don't put them on a timeline. But the way you should continue to see at minimum is continued bolt-on acquisitions. In the segments -- of the deals that we did -- the deals this quarter, again, none of them were competitive. They weren't processes. I think we don't -- at least the deals we're doing, we're not seeing a big change in any kind of pricing environment. So I guess that answers the question.

    當然。我認為我們的併購策略一向會是在你提到的補強型(tuck-ins 或 bolt-ons)與機會性的大型收購之間取得平衡。沒有人能預測大型收購的時點,所以當它們發生時就會發生。我們不會把它們放在時間表上。但你們至少應該會持續看到的是:我們會繼續進行補強型收購。就我們做的交易——本季的交易而言,再次強調,沒有一筆是競標型的。它們不是流程式的拍賣案。我想我們——至少就我們正在做的交易來看——並沒有看到任何定價環境出現很大的變化。所以我想這就回答了你的問題。

  • Operator

    Operator

  • David Amsellem, Piper Jaffray.

    David Amsellem,Piper Jaffray。

  • - Analyst

    - Analyst

  • So with the recent 500% price increase on Glumetza in mind, can you talk about the extent to which you envision more pricing power, not just for other products acquired by the Salix transaction, but maybe just your assets, broadly speaking, in the US? How should we think about that? Thank you.

    考量到近期 Glumetza 調價 500% 的情況,你能談談你們預期還有多少定價能力嗎?不僅是 Salix 交易所取得的其他產品,或許也包括你們在美國的資產,從更廣泛的角度來看。我們應該如何思考這件事?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • I think most pharma companies that I'm aware of, as the product gets into the last stages of their life, like Glumetza -- we're going to lose Glumetza within six months -- often price increases are taken at the end. So that was just consistent with what most companies do.

    我認為就我所了解的大多數製藥公司而言,當產品進入其生命週期的最後階段時,例如 Glumetza——我們會在六個月內失去 Glumetza——通常會在末期進行調價。所以那只是與多數公司做法一致。

  • Our view on pricing -- across most of our portfolio, we do not take prices. Outside the US, there's like zero price. I think, David, as we get more and more into segments like contact lenses and consumer products and other devices, we're not able to take price. So we're opportunistic when it comes to price. But our base strategy is, how do we grow organically through volume, which is -- I think this quarter, we once again exhibited our ability to do so.

    我們對定價的看法是——在我們大多數產品組合中,我們不會調漲價格。在美國以外,幾乎沒有漲價空間。我想,David,隨著我們越來越深入隱形眼鏡、消費性產品及其他器材等細分領域,我們就更無法漲價。所以在價格方面我們會把握機會、視情況而定。但我們的基本策略是:如何透過銷量來推動內生成長——我認為本季我們再次展現了這方面的能力。

  • Operator

    Operator

  • Tim Chiang, BTIG.

    Tim Chiang,BTIG。

  • - Analyst

    - Analyst

  • Mike, I think in past quarters I've asked you about Emerade. Is there any update on Emerade? Is that a product that you're still targeting for US launch, sometime, what? Late next year? Early 2017?

    Mike,我想在過去幾季我都問過你關於 Emerade 的事。Emerade 有任何最新進展嗎?這個產品你們仍然以在美國上市為目標嗎?大概什麼時候?明年下半年?2017 年初?

  • - Chairman & CEO

    - Chairman & CEO

  • Yes, we are still hoping to get that product approved in the US. We have a meeting with the FDA coming up. So why don't we update you on the next quarter on that? Hopefully, we can agree on the timing and the path with the FDA. But before we have that meeting, I don't want to guess.

    是的,我們仍希望讓該產品在美國獲得核准。我們即將與 FDA 開會。所以不如我們在下個季度再向你更新?希望我們能與 FDA 就時程與路徑達成一致。但在開會之前,我不想猜測。

  • - Analyst

    - Analyst

  • Okay, great, thanks.

    好的,非常好,謝謝。

  • Operator

    Operator

  • Gregg Gilbert, Deutsche Bank.

    Gregg Gilbert,德意志銀行。

  • - Analyst

    - Analyst

  • On the Salix increased guidance, is that all IBS? Or are there some other drivers? Can you also share with us what the gross to net is for Xifaxan at this point? Thanks.

    關於 Salix 上調指引,那全部都是 IBS 帶動的嗎?還是有其他驅動因素?你們也能分享一下目前 Xifaxan 的 gross-to-net(毛額到淨額折讓)是多少嗎?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Rob, why don't you answer the gross to net question?

    Rob,你來回答 gross-to-net 的問題好嗎?

  • But first, in terms of the revenue increase in Salix -- what we modeled in, yes, is IBS-D. Some of the other products are doing a little bit better than our forecast. But we wanted to be prudent in terms of raising our guidance. So the rates, the $200 million raised for IBS-D is what's included in the guidance.

    不過先談 Salix 的營收上修——我們納入模型的,沒錯,是 IBS-D。其他一些產品的表現也略優於我們的預測。但我們在上調指引時希望保持審慎。因此,指引中包含的是 IBS-D 上調的 2 億美元。

  • - CFO

    - CFO

  • Our forecast for gross to net is 30%.

    我們對 gross-to-net 的預測是 30%。

  • Operator

    Operator

  • Alex Arfaei, BMO Capital.

    Alex Arfaei,BMO Capital。

  • - Analyst

    - Analyst

  • Congratulations on a strong quarter. Welcome, Rob.

    恭喜本季表現強勁。歡迎你,Rob。

  • Can you provide more details of the profitability of the Amoun business? Possible synergies? How accretive the deal could be? Thank you.

    你能提供更多關於 Amoun 業務獲利能力的細節嗎?可能的協同效益?這筆交易可能有多大的增益(accretive)?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Yes. Amoun -- their operating margin today is sort of mid-30%s; so 35% is probably a good proxy. So it should be, actually, quite accretive. We don't know the exact timing of close. Our partners -- or the private equity company we purchased it from thinks we'll close in the third quarter. But we've built in fourth quarter close.

    可以。Amoun——他們目前的營業利益率大約在 30% 中段;所以 35% 可能是個不錯的代表值。因此實際上應該會相當具增益性。我們還不確定確切的交割時間。我們的合作夥伴——也就是我們向其收購的私募股權公司——認為會在第三季完成交割。但我們在規劃上是以第四季交割為前提。

  • We need to meet with the Minister of Health in Egypt. The process is not as clear in Egypt as it is in some countries. But it should be quite accretive. We will obviously get some synergies from this deal as well. The synergies may come more on the Valeant side than on the Amoun side. But as we consolidate our Middle East and Northern African business, we do expect to maintain and maybe even accelerate the growth rates of that business.

    我們需要與埃及衛生部長會面。埃及的流程不像某些國家那麼清楚。但這筆交易應該會相當具增益性。我們當然也會從這筆交易中取得一些協同效益。協同效益可能更多來自 Valeant 端,而不是 Amoun 端。但隨著我們整合中東與北非業務,我們預期能維持,甚至可能加速該業務的成長率。

  • Operator

    Operator

  • Marc Goodman, UBS.

    Marc Goodman,瑞銀。

  • - Analyst

    - Analyst

  • Mike, on slide 13, you started to go through some of the organic growth you were seeing in different parts of the world. Could you go into a little more detail just on Russia, China, some of these emerging markets, and what you're seeing? Because, clearly, the rest of the industry is struggling in these regions. Thanks.

    Mike,在第 13 張投影片,你開始談到你們在世界不同地區看到的一些內生成長。你能否就俄羅斯、中國等一些新興市場再多談一點,說說你們看到的情況?因為很明顯,產業其他公司在這些地區都很吃力。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • So Russia, we had a tougher first quarter, as you may recall. Part of that was, everyone was buying like crazy in the fourth quarter. So Russia, we're very pleased. We have a great team over there, are very pleased to see that organic growth has not returned -- it used to be growing there about 15% -- but 7%, we're satisfied with for this quarter. Obviously, we'd like to get back to double digits. But we're very pleased to get that back.

    俄羅斯方面,我們第一季比較艱難,你可能還記得。部分原因是大家在第四季都在瘋狂採購。所以俄羅斯這邊我們非常滿意。我們在那裡有很棒的團隊,也很高興看到內生成長回來了——以前那邊大約成長 15%——但本季 7% 我們也算滿意。當然,我們希望能回到兩位數成長。但能把成長拉回來,我們非常高興。

  • China -- we just have a great team over there. It's just again, you may remember an acquisition of Bescon last year. Those aren't actually in organic growth, they're probably still in pro forma. But with some new colored contact lenses. But we've launched BioTrue daily in China. It's really taking off. They're just doing a great job. I think a lot of this is driven in China and North Asia by the B+ L business. Again, I think we have a set of newer products that are allowing us to maintain the growth and gain share. But I would really point to our people as the main reason we're doing so well.

    中國——我們在那裡也有非常棒的團隊。再說一次,你可能記得我們去年收購了 Bescon。那些其實不算在內生成長裡,可能仍然是以 pro forma 方式呈現。另外還有一些新的彩色隱形眼鏡。但我們已在中國推出 BioTrue 日拋。表現真的正在快速起飛。他們做得非常出色。我認為在中國與北亞,很多成長是由 B+L 業務所帶動。同樣地,我認為我們有一系列較新的產品,使我們能維持成長並提升市占。但我真的要把我們表現這麼好的主要原因歸功於我們的團隊。

  • Operator

    Operator

  • Gary Nachman, Goldman Sachs.

    Gary Nachman,高盛。

  • - Analyst

    - Analyst

  • Nice quarter.

    本季表現不錯。

  • Now that you've filed Vesneo and Relistor Oral, what are some of the commercial initiatives you're thinking about with those products? How will they be differentiated in their respective markets? How big do you think they could be? Thanks a lot.

    既然你們已經遞交 Vesneo 和 Relistor 口服劑型的申請,你們對這些產品有哪些商業化推動措施的想法?它們在各自市場中會如何差異化?你們認為它們的規模可能有多大?非常感謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Yes. Gary, we haven't done a lot of work yet on the launch plan for Relistor Oral. We've just got to file, so it's probably -- we hope to get it approved next year. But what's great about this product is, it's fast-acting. Competitor products, I think, act within a couple days. Our product will act within three, four hours; for most people, it reacts right away -- 30 minutes. Since you -- if you're super-constipated, fast-acting is good.

    是的。Gary,我們對 Relistor 口服劑型的上市計畫目前還沒有做太多工作。我們才剛完成申報,所以大概——我們希望明年能獲准。但這個產品很棒的一點是,它起效很快。我認為競品通常要一兩天才起效。我們的產品在三、四小時內就會起效;對大多數人來說,反應幾乎是立刻——30 分鐘。如果你便秘非常嚴重,起效快是好事。

  • Also, what we're finding is, it's actually a product that helps save the healthcare system money. If you're at a hospital, you're not allowed to be discharged until you have a bowel movement. So it's a product that I think is -- this is going to be a premium product based on helping healthcare economics. All that means is that we really haven't laid out our full sales and marketing plan. But we'll start doing that now that it's filed.

    另外,我們發現它其實是一個能幫醫療體系省錢的產品。如果你在醫院,沒有排便之前是不允許出院的。所以我認為這會是一個基於改善醫療經濟效益而具備溢價能力的產品。這些都意味著我們確實還沒有完整擬定我們的銷售與行銷計畫。但既然已經申報,我們現在就會開始著手。

  • Operator

    Operator

  • Douglas Tsao, Barclays.

    Douglas Tsao,巴克萊。

  • - Analyst

    - Analyst

  • Mike, maybe on Jublia, if you could just elaborate, given the transition to 8 mL? I'm curious what you're seeing in terms of the gross to nets on that product versus the 4 mL? Then also, are you seeing comparable coverage from managed care? Or are you seeing any sort of limitations in terms of quantities and refills the patients are able to get? Thank you.

    Mike,或許談談 Jublia,你能否就轉換到 8 mL 再多說明一下?我想了解你們在該產品的毛額到淨額(gross-to-net)方面,相較於 4 mL 看到的情況如何?另外,你們是否看到來自管理式醫療(managed care)相當的給付覆蓋?或者在病患可取得的數量與續配(refills)方面,你們是否看到任何限制?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • I'm going to let Ari take that question; he's closer to it.

    我讓 Ari 來回答這個問題;他更貼近這部分。

  • - Company Group Chairman

    - Company Group Chairman

  • Yes. The uptake on the 8 mL has been strong. It's just running under -- as we've said around 29%. In terms of the gross to nets, we're in ongoing discussions with managed care. We suspect the gross to nets will be no worse than and probably better than the 4 mL.

    是的。8 mL 的採用情況很強勁。如同我們所說,大約略低於——約 29%。就毛額到淨額而言,我們正與管理式醫療持續討論中。我們推測毛額到淨額不會比 4 mL 更差,而且很可能會更好。

  • - Analyst

    - Analyst

  • Which is? Then also just in terms of the limitations on refills? If any?

    也就是?另外就續配的限制而言?如果有的話?

  • - Company Group Chairman

    - Company Group Chairman

  • Well, the label, as you know, requires treatment up to 48 weeks; that is what we're promoting. Physicians understand that this product needs to be taken for a duration of therapy to achieve the desired result. Refills are tracking very nicely.

    嗯,標籤(label)如你所知,要求治療最長可達 48 週;這也是我們在推廣的內容。醫師了解這個產品需要服用一段療程,才能達到預期效果。續配的追蹤表現非常好。

  • - Chairman & CEO

    - Chairman & CEO

  • Yes, so what we -- many people have multiple toes that are affected. So we're seeing the refill rates on the 8 mL to be quite comparable to the 4 mLs, if that's what you're asking.

    是的,所以我們——很多人有多個腳趾受到影響。因此我們看到 8 mL 的續配率與 4 mL 相當接近,如果你問的是這個。

  • Operator

    Operator

  • David Risinger, Morgan Stanley.

    David Risinger,摩根士丹利。

  • - Analyst

    - Analyst

  • Yes. I guess my first question is, I'm wondering if the -- you're trying to suggest with the background noise that you may be onsite doing due diligence on a duck farming business. (laughter) We don't want you diversifying -- we don't want you diversifying that much. (laughter)

    是的。我想我的第一個問題是,我在想——你們是不是想用那些背景噪音暗示你們正在現場對一門養鴨生意做盡職調查。(笑聲) 我們不希望你們多角化——我們不希望你們多角化到那種程度。(笑聲)

  • But my real question is, with respect to cash flow, obviously, you've provided an upgraded adjusted cash flow guidance of over $3.2 billion. Could you provide some more color on GAAP cash flow? How we should think about that in the back half of the year? Then one tidbit of a question -- could you just, Mike, tell us in a little bit more detail, the timing of when you're assuming Glumetza generics launch? Thank you.

    但我真正的問題是,關於現金流,顯然你們已將調整後現金流指引上調至超過 32 億美元。你們能否就 GAAP 現金流提供更多說明?我們應該如何看待今年下半年?另外一個小問題——Mike,你能否更詳細告訴我們,你們假設 Glumetza 學名藥何時上市的時間點?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • I think Glumetza generics -- is it February?

    我想 Glumetza 學名藥——是二月嗎?

  • - Head of IR

    - Head of IR

  • Yes.

    是的。

  • - Chairman & CEO

    - Chairman & CEO

  • Early February of next year. We can get you the precise date. But that's -- so we assume we have it for the rest of this year.

    明年二月初。我們可以給你確切日期。但就是——所以我們假設今年剩下的時間我們仍然擁有它。

  • In terms of GAAP cash flow -- Rob, do you want to take that one?

    至於 GAAP 現金流——Rob,你要不要回答這題?

  • - CFO

    - CFO

  • Yes. Here's what I'd say: with respect to the $3.2 billion overall, until this inventory situation that we are in is resolved, we're being conservative. What we described on the disaggregation was, when you look at the GAAP cash flow for Valeant excluding Salix, it was very strong. As we work through both the inventory on Salix as well as these largely one-time items that hit in Q2, you're going to see an acceleration in our overall GAAP cash flow.

    是的。我會這麼說:就整體 32 億美元而言,在我們目前所處的這個庫存狀況解決之前,我們會採取保守態度。我們在拆分說明中提到的是,當你看 Valeant 的 GAAP 現金流(不含 Salix)時,其實非常強勁。當我們同時消化 Salix 的庫存以及第二季影響的這些大多屬一次性項目時,你會看到我們整體 GAAP 現金流加速改善。

  • - Chairman & CEO

    - Chairman & CEO

  • Yes. In terms of GAAP cash flow, obviously, it will converge to adjusted cash flow over time. The big components are -- we've taken all the expenses for all the severances in this quarter for Salix; it's largely driven by Salix. So there should be a ton-ton more charges. I think that next quarter, GAAP will still be probably a big -- a significant difference. But by fourth quarter, we should be in a pretty good place.

    是的。就 GAAP 現金流而言,顯然它會隨時間與調整後現金流趨於一致。主要組成是——我們在本季已把 Salix 所有遣散相關費用全部入帳;主要是由 Salix 所驅動。因此不會再有大量的費用。我認為下季 GAAP 可能仍會有很大——相當顯著的差異。但到第四季,我們應該會處在相當好的狀態。

  • The only piece that will be lingering is, the severance agreement for Salix with some employees paid out over -- rather than a one-time payment, they were paid out over 12 months, or 24 months in some cases. So there'll be some small cash component. We did not accelerate that for obvious reasons. But we probably will offer a program where people who want to get accelerated, at a discount we'll give it. But I think by fourth quarter, you should see some [nuke] and convergence. I do think this will be the most extreme -- Q2 will be the most extreme quarter.

    唯一仍會持續的是,Salix 與部分員工的遣散協議是分期支付——不是一次性支付,而是分 12 個月支付,有些情況是 24 個月。所以會有一些小額的現金支出部分。基於顯而易見的原因,我們沒有加速支付。但我們可能會提供一個方案,讓想要加速領取的人以折扣方式提前領取。不過我認為到第四季,你應該會看到一些 [nuke] 以及趨同。我確實認為這會是最極端的——第二季會是最極端的一季。

  • Operator

    Operator

  • Corey Davis, Canaccord Genuity.

    Corey Davis,Canaccord Genuity。

  • - Analyst

    - Analyst

  • So if gross margin is going to be running at close to 80% by the end of the year, without giving formal guidance for 2016 directionally, can you tell us how we should think about that going into 2016?

    所以如果毛利率到年底將接近 80%,在不提供 2016 年正式指引的前提下,你們能否方向性地告訴我們,進入 2016 年我們應該如何看待?

  • - Chairman & CEO

    - Chairman & CEO

  • We certainly plan to get to 80% by next year. We'll see if we get there by the fourth quarter or not. Then, over time, we should -- again, absent any other big deal, which could have an impact on it, I think gross margins will continue to improve.

    我們確實計畫在明年達到 80%。至於是否能在第四季達到,我們再看看。然後,隨著時間推進,我們應該——同樣地,在沒有其他大型交易(可能會影響它)的情況下,我認為毛利率會持續改善。

  • - Analyst

    - Analyst

  • One quick follow-up on an earlier question on Vesneo: are you still feeling as good on that one as you have in the past? Have you developed a commercial plan for that yet?

    針對先前關於 Vesneo 的問題快速追問:你們對它的信心是否仍像過去一樣高?你們是否已為它制定商業化計畫?

  • - Company Group Chairman

    - Company Group Chairman

  • As Mike mentioned, we've filed Vesneo. We still feel optimistic about the product, as we've discussed in the past -- the unique mechanism of action for this minor therapy, and the nitric oxide-donating piece of it. We have had, obviously, since the last call, many more discussions with KOL. So we remain optimistic about the prospects of this product. Its approval expected next year.

    如 Mike 提到的,我們已提交 Vesneo 的申請。我們仍對該產品保持樂觀,正如我們過去討論的——這項輕度療法的獨特作用機轉,以及其一氧化氮供體(nitric oxide-donating)的部分。顯然,自上次電話會議以來,我們與 KOL(關鍵意見領袖)進行了更多討論。因此我們仍對這個產品的前景保持樂觀。預期明年獲批。

  • - Analyst

    - Analyst

  • Great, thank you very much.

    很好,非常感謝。

  • Operator

    Operator

  • Douglas Miehm, RBC Capital.

    Douglas Miehm,RBC Capital。

  • - Head of IR

    - Head of IR

  • Doug? We'll go on to the next call.

    Doug?我們先進行下一通。

  • Operator

    Operator

  • Glenn Greenberg, Brave Warrior Advisors.

    Glenn Greenberg,Brave Warrior Advisors。

  • - Analyst

    - Analyst

  • Quick question -- on Salix, you've said the revenues this year would be about $1.2 billion. It looks like they were $300 million in the last quarter and will be $300 million again in the third quarter. So does that imply that the fourth quarter revenues would be $600 million? That we could maybe annualize that or a little better as we look into its contribution to revenues next year?

    快速一問——關於 Salix,你們說今年營收大約會是 12 億美元。看起來上一季是 3 億美元,第三季也會再是 3 億美元。那是否意味著第四季營收會是 6 億美元?我們是否可以把它年化,或在我們展望明年其對營收貢獻時,預期略高一些?

  • - Chairman & CEO

    - Chairman & CEO

  • Yes. We're projecting $600 million for the fourth quarter. The $1.2 billion in the end may prove a little conservative; it depends. It's just hard to know all the inventory that could be out there. But the business is also accelerating. The growth continues to be very strong. Certainly, by first quarter of next year, we should be selling to full demand. So if you incorporate maybe a slight bit of inventory is still in the channel in the fourth quarter, we don't know. That's what we're assuming. Then you continue to model in the growth that we're experiencing across the brands, that should give you a pretty good feel for what this thing will look like for next year.

    是的。我們預估第四季為6億美元。最終的12億美元可能會顯得稍微保守一些;這要看情況。因為很難掌握通路裡可能還有多少庫存。但業務也正在加速。成長仍然非常強勁。當然,到了明年第一季,我們應該會以滿足全部需求的狀態在銷售。所以如果你把第四季通路裡可能仍有一點點庫存納入考量,我們也不確定。這就是我們的假設。接著你再把我們在各品牌上所經歷的成長持續納入模型,應該就能相當清楚地掌握明年會是什麼樣子。

  • - Analyst

    - Analyst

  • Okay. One further point -- how did you make such improvement on the gross margin there?

    好的。再問一點——你們是如何在毛利率上做出這麼大的改善?

  • - Chairman & CEO

    - Chairman & CEO

  • In which -- you mean overall? Or --?

    你指的是——整體嗎?還是——?

  • - Analyst

    - Analyst

  • Yes, In the Salix (inaudible).

    是的,在Salix(聽不清)。

  • - Chairman & CEO

    - Chairman & CEO

  • In the Salix. Well, a lot of it, again, there's a lot of discounting going on.

    在Salix。嗯,其中很大一部分原因是,還是有很多折扣在進行。

  • - Analyst

    - Analyst

  • Okay.

    好的。

  • - Chairman & CEO

    - Chairman & CEO

  • In terms of -- in inventory in the channel. So we're obviously just selling to demand.

    就——通路庫存而言。所以我們顯然只是按需求出貨。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • David Steinberg, Jefferies.

    Jefferies的David Steinberg。

  • - Analyst

    - Analyst

  • Just wanted to follow-up on the Jublia question. You mentioned the change in the gross to nets, but did the -- especially, did the number of scrips going through the specialty pharmacy improve? I think it was about 50% last time. Secondly, given the strength in some of your other derm products, Onexton and Luzu, what percent of those scrips are through your specialty pharmacy channels? Thanks.

    我想追問一下關於Jublia的問題。你提到毛額到淨額(gross-to-nets)的變化,但——尤其是,經由專科藥局處理的處方數(scrips)是否有改善?我記得上次大約是50%。第二,鑑於你們其他一些皮膚科產品Onexton和Luzu的強勁表現,那些處方中有多少比例是透過你們的專科藥局通路?謝謝。

  • - Company Group Chairman

    - Company Group Chairman

  • Yes, the adoption through multiple specialty pharmacies continues. I think last time we said Jublia was around 50%. That trend continues. For derm overall, it varies by product, but it's around 40%.

    是的,透過多家專科藥局的採用率仍在持續。我想上次我們說Jublia大約是50%。這個趨勢仍在延續。至於皮膚科整體,會因產品而異,但大約是40%。

  • Operator

    Operator

  • Alan Ridgeway, Scotiabank.

    Scotiabank的Alan Ridgeway。

  • - Analyst

    - Analyst

  • Mike, you commented in your prepared remarks about the number of commercial lines for contact lenses, now planned to be five or six. Can you maybe just comment on what you guys are seeing in the market as far as what gives you comfort that you'll be able to fill up that capacity? I'll leave it at that. Thanks.

    Mike,你在事先準備的發言中提到隱形眼鏡的商業產線數量,現在規劃為五到六條。你能否談談你們在市場上看到的情況,哪些因素讓你們有信心能把這些產能填滿?我就問到這裡。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Sure. We talked about the two platforms that are really growing. One is BioTrue daily. I think, there, we're increasing by five or six. Then the second being ULTRA; there, we're increasing by -- we're going up to six. We only have -- we currently have one installed. The size of the lines are quite different. BioTrue has much lower capacity than an ULTRA line, so that accounts for why so many more BioTrues than ULTRAs. It's probably close to 2 to 1. So it's probably about the same level of expansion.

    當然。我們談到兩個真正正在成長的平台。一個是BioTrue日拋。我想在那裡,我們會增加五到六條。第二個是ULTRA;那裡我們會增加到——提升到六條。我們目前只——現在只裝設了一條。各產線的規模差異很大。BioTrue的產能遠低於ULTRA產線,因此這也解釋了為什麼BioTrue的產線數會比ULTRA多很多。大概接近2比1。所以整體擴產幅度大概差不多。

  • What gives us comfort is, first -- well, in the case of ULTRA, right now, we're only selling in the US. The other markets are clamoring for it. We're probably going to expand in the next quarter to a few more countries. But we have the whole rest of the world and we can't satisfy demand in the US. BioTrue daily, again, in the US, for example, is growing 4 times the growth rate of the segment.

    讓我們有信心的原因,首先——嗯,以ULTRA為例,目前我們只在美國銷售。其他市場都在強烈要求引進。我們可能會在下一季擴展到另外幾個國家。但我們還有全球其他市場,而我們在美國都無法滿足需求。至於BioTrue日拋,同樣地,以美國為例,其成長速度是該細分市場成長率的4倍。

  • When we model out what we think our final share will be and how quickly -- we're going to need this capacity. I think what we have is a reenergized sales forces around the world. Maybe most important, eye care professionals, especially in the contact lens area -- Ari, our source -- we need to see that B+ L back in the game. You may want to comment further.

    當我們建模推估最終市占會是多少,以及需要多快——我們將需要這些產能。我認為我們擁有一支在全球重新振作的銷售團隊。也許最重要的是,眼科照護專業人士,尤其是在隱形眼鏡領域——Ari,我們的消息來源——我們需要看到B+L重新回到賽局。你可能想再補充一下。

  • - Company Group Chairman

    - Company Group Chairman

  • Yes, I think that as Mike said, both the BioTrue as well as ULTRA is demonstrating the impact of the terrific technologies that B+ L had been developing that we're fortunate to have received. It really is new technology, with better comfort, better oxygenation, and better hydration and comfort throughout the day. Eye care practitioners in the end of the day are trying to deliver outstanding products to their patients. We're simply enabling that. Hence the growth in share in the US for both of those platforms. Again as Mike had said earlier, tremendous growth across Asia, China, Korea, Japan, and elsewhere in the world with these new technologies.

    是的,我想如Mike所說,BioTrue以及ULTRA都展現了B+L一直在研發、而我們很幸運得以取得的卓越技術所帶來的影響。這確實是新技術,具備更好的舒適度、更好的透氧性,以及更好的保濕,並能在一天當中維持水潤與舒適。眼科照護從業者歸根結底是希望為病患提供出色的產品。我們只是讓他們能做到這一點。因此這兩個平台在美國的市占都在成長。同樣如Mike先前所說,這些新技術在亞洲、中國、韓國、日本以及全球其他地區也帶來了驚人的成長。

  • Operator

    Operator

  • We have no further questions. I'll turn the call back to you for closing remarks.

    我們沒有其他問題了。我把電話交回給你做結語。

  • - Chairman & CEO

    - Chairman & CEO

  • Great. Well, thanks everyone for your questions. I guess it's time to get back to work. We'll talk to you next quarter.

    很好。謝謝大家的提問。我想是時候回去工作了。我們下個季度再聊。

  • Operator

    Operator

  • This does conclude today's conference call. You may now disconnect.

    今天的電話會議到此結束。您現在可以掛線。